Bcwm LLC Invests $1.98 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bcwm LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,766 shares of the medical equipment provider's stock, valued at approximately $1,982,000.

Several other large investors have also bought and sold shares of the company. United Bank lifted its stake in Zimmer Biomet by 6.7% during the fourth quarter. United Bank now owns 9,426 shares of the medical equipment provider's stock valued at $996,000 after purchasing an additional 589 shares during the last quarter. Allianz SE acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $3,099,000. Intrust Bank NA lifted its holdings in shares of Zimmer Biomet by 31.4% during the fourth quarter. Intrust Bank NA now owns 2,872 shares of the medical equipment provider's stock valued at $303,000 after purchasing an additional 687 shares during the last quarter. Allstate Corp acquired a new stake in Zimmer Biomet during the 4th quarter worth about $669,000. Finally, DnB Asset Management AS lifted its stake in Zimmer Biomet by 2.7% during the fourth quarter. DnB Asset Management AS now owns 36,997 shares of the medical equipment provider's stock valued at $3,908,000 after buying an additional 957 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is owned by company insiders.

Remove Ads

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded up $0.98 during midday trading on Thursday, hitting $113.48. 1,001,581 shares of the company were exchanged, compared to its average volume of 1,568,294. The firm has a 50 day simple moving average of $107.35 and a 200-day simple moving average of $107.18. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $22.59 billion, a P/E ratio of 25.50, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $130.89.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the business posted $2.20 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several recent analyst reports. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Barclays decreased their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.